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Enhanced renoprotective effects of ultrahigh doses of irbesar-
tan in patients with type 2 diabetes and miroalbuminuria.
Background. The purpose of this study was to evaluate the
renoprotective effect as reflected by short-term changes in al-
buminuria of ultrahigh doses of irbesartan in type 2 diabetic
patients with microalbuminuria.
Methods. This double-masked randomized crossover trial in-
cluded 52 (41 males) hypertensive type 2 diabetic patients with
microalbuminuria on ongoing antihypertensive medication. At
inclusion, previous antihypertensive treatment was discontin-
ued and replaced with bendroflumethiazide, 5 mg once daily, for
the entire study. Following 2 months wash-out (baseline), pa-
tients were treated randomly with irbesartan 300, 600, and 900
mg once daily, each dose for 2 months. End points evaluated at
the end of each study period included urinary albumin excretion
rate (UAE) (mean of three 24-hour collections), 24-hour am-
bulatory blood pressure, and glomerular filtration rate (GFR)
[chromium 51 ethylenediaminetetraacetic acid (51Cr-EDTA)].
Results. Baseline values were: 24-hour UAE [geometric mean
(95% CI)] 134 (103 to 170) mg/24 hours, ambulatory blood pres-
sure [mean (SD)] 140 (10)/77 (7) mm Hg, and GFR 103 (19)
mL/min/1.73 m2. All doses of irbesartan significantly reduced
UAE, ambulatory blood pressure, and GFR from baseline. Re-
ductions in UAE from baseline were 52% (46% to 57%), 49%
(43% to 54%), and 59% (54% to 63%) with increasing doses
of irbesartan (P < 0.01). UAE was reduced significantly more
by irbesartan 900 mg compared with lower doses with an addi-
tional reduction in UAE of 15% (2% to 26%) by irbesartan 900
mg compared with 300 mg (P = 0.02). The greater reduction in
albuminuria by irbesartan 900 vs. 300 mg was more pronounced
in patients with UAE during irbesartan 300 mg above vs. below
the median [31% (18% to 42%) vs. −9% (−25% to 6%), re-
spectively (P < 0.05)].
With increasing doses systolic ambulatory blood pressure was
reduced from baseline by 8 (4 to 12), 9 (5 to 13), and 9 (5 to13)
mm Hg, and diastolic ambulatory blood pressure by 6 (4 to 7),
7 (6 to 9), and 7 (6 to 9) mm Hg (NS between doses).
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Conclusion. Ultrahigh dosing of irbesartan (900 mg once
daily) is generally safe and offers additional renoprotection in-
dependent of changes in systemic blood pressure and GFR in
comparison to the currently recommended dose of 300 mg.
At present more than 170 million people worldwide
have diabetes and the number is expected to double
within the next 20 years mainly due to an epidemic in-
crease in the prevalence of type 2 diabetes [1]. Diabetes
is associated with an increased occurrence of cardiovascu-
lar disease and approximately 40% of all diabetic patients
are at risk of developing diabetic nephropathy which
has become the leading cause of end-stage renal disease
(ESRD) in the Western world [2]. Therefore, the early
identification and subsequent end-organ protective treat-
ment of all patients at risk are of outmost importance.
In this regard patients with persistent microalbuminuria
[urinary albumin excretion (UAE) between 30 and 300
mg/24 hours] have a 10 to 20 times increased risk of de-
veloping diabetic nephropathy as compared to patients
with normoalbuminuria [2]. In addition, the occurrence
of microalbuminuria is associated with a highly increased
risk of premature death due to cardiovascular disease [3].
Reduction of UAE by blockade of the renin-
angiotensin-aldosterone system (RAAS) has emerged as
a key treatment goal for both reno- and cardiovascular
protection [4–10]. Data from the large clinical Irbesartan
in Patients with Type 2 Diabetes and Microalbuminuria
(IRMA2) Study [11] firmly demonstrated that treatment
with the angiotensin II receptor blocker (ARB) irbesar-
tan reduces UAE and the risk of progression to overt di-
abetic nephropathy in patients with type 2 diabetes and
persistent microalbuminuria. Furthermore, in type 2 di-
abetic patients with more advanced renal disease, ARBs
have been shown to reduce the risk of reaching the com-
bined renal end point of doubling in serum creatinine,
ESRD, or death [12, 13]. Since 2002, ARBs have con-
sequently been recommended as first-line therapy in hy-
pertensive type 2 diabetic patients with microalbuminuria
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Fig. 1. Crossover study evaluating the effi-
cacy and safety of irbesartan (Irb) 300, 600.
and 900 mg once daily in 52 type 2 diabetic pa-
tients with microalbuminuria. The study con-
sisted of an initial 8-week washout period with
discontinuation of all previous antihyperten-
sive medication and with initiation of ben-
droflumethiazide 5 mg daily in all patients.
Following the washout period, patients were
treated in random order with irbesartan 300,
600, and 900 mg once daily. Each treatment
period consisted of an initial 2 weeks’ titra-
tion period with irbesartan 300 mg followed
by 8 weeks with daily doses of irbesartan of
300, 600, and 900 mg, respectively. End points
were evaluated after the initial washout pe-
riod (baseline and at the end of each of the
three treatment periods).
or clinical albuminuria according to guidelines from the
American Diabetes Association [14].
Despite the proven benefit of treatment with irbesartan
in preventing diabetic nephropathy the optimal renopro-
tective dose remains unknown. Inadequate dosing may in
part be responsible for the development and progression
of diabetic renal disease in some patients. In the IRMA2
study, irbesartan 300 mg once daily was superior to irbe-
sartan 150 mg once daily in reducing UAE and prevent-
ing the development of overt diabetic nephropathy [11].
However, 2.5% per year of patients developed diabetic
nephropathy despite treatment with irbesartan 300 mg
once daily in addition to conventional blood pressure–
lowering agents. Doses of irbesartan above 300 mg daily
have not been evaluated. Consequently it remains un-
known if the full renoprotective potential is reached by
currently recommended doses, which are based on the
blood pressure–lowering effects in patients with primary
hypertension [15]. However, higher doses may be needed
for a more complete end-organ protection in patients with
diabetic renal disease.
The aim of the present study was therefore to evalu-
ate the safety and antiproteinuric efficacy of irbesartan
by doses exceeding the present maximum recommended
dose of 300 mg once daily in patients with type 2 diabetes
and microalbuminuria.
METHODS
Patients
All patients were recruited from the Steno Diabetes
Center. Patients included in the study were type 2 dia-
betic patients [World Health Organization (WHO) cri-
teria], with microalbuminuria (persistent UAE between
30 and 300 mg/24 hours, ∼ 20 to 200 lg/min) on ongoing
antihypertensive medication implying that patients were
not excluded if UAE increased above 300 mg/24 hours
after withdrawal of previous treatment. Patients were ex-
cluded if they had a known nondiabetic kidney or renal
tract disease, serum potassium values >4.6 mmol/L, sys-
tolic blood pressure <100 mm Hg during antihyperten-
sive treatment or systolic blood pressure persistently
>180 mm Hg and/or diastolic blood pressure >105 mm
Hg upon discontinuation of previous antihypertensive
treatment.
Design
The study consisted of an 8-week washout period of
all previous antihypertensive medication followed by a
double-masked randomized crossover trial with three 10-
week treatment periods (Fig. 1). Randomization was con-
cealed with computer-generated envelopes. The code was
not broken until all data were entered into a database,
which was locked for editing.
The washout period. Eight weeks prior to random-
ization all previous antihypertensive medication was dis-
continued and treatment with bendroflumethiazide 5 mg
once daily was initiated in all patients and continued at
5 mg once daily throughout the entire study. During the
8-week washout period, blood pressure was monitored at
home by the patients two times daily three times a week
with an automatic blood pressure measuring device to en-
sure that blood pressure did not exceed the safety limit
of the study (>180/105 mm Hg).
Double-blind crossover periods. All treatment peri-
ods were of 10 weeks’ duration and consisted of an initial
2-week dose titration period with irbesartan 300 mg once
daily followed by 8 weeks’ treatment with irbesartan 300,
600, and 900 mg once daily, respectively. All patients re-
ceived treatment with irbesartan 300, 600, and 900 mg
once daily in random order.
For safety reasons arterial blood pressure, plasma
potassium, and plasma creatinine were measured 4 weeks
after the beginning of each treatment period (2 weeks af-
ter the full dose of the treatment period was reached).
End points of the study were evaluated after the
washout period (baseline) and at the end of each three
treatment periods with irbesartan. The primary end
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point was UAE measured as geometric mean from three
consecutive 24-hour urinary collections. Secondary end
points included 4-hour UAE measured during the clear-
ance procedure, fractional clearance of albumin, ambula-
tory blood pressure, and glomerular filtration rate (GFR).
The local ethical committee approved the study, and all
patients gave their informed consent to participate in the
study after the nature of the study had been explained.
The study was performed in accordance with the Helsinki
Declaration.
Laboratory procedures
UAE in the 24-hour and 4-hour urine samples was de-
termined by turbidimetry (Hitachi 912 system) (Roche
Diagnostics, Mannheim, Germany). Urinary sodium,
potassium, creatinine, and urea excretion were deter-
mined from the 24-hour urine samples (Hitachi 912 sys-
tem). To eliminate changes in UAE caused by variation in
plasma albumin and GFR, we determined the fractional
clearance of albumin (halbumin) during the 4-hour clear-
ance procedure as [UAE]/[(plasma albumin concentra-
tion) × (GFR)], where UAE was measured in the 4-hour
urine collection during GFR determination.
Blood pressure was measured by a 24-hour ambulatory
blood pressure device (Takeda TM2421) (A & D Medi-
cal, Tokyo, Japan). Blood pressure was measured every
15 minutes during the day (7:00 a.m. to 11:00 p.m.) and ev-
ery 30 minutes during the night (11:00 p.m. to 7:00 a.m.).
Values were averaged for each hour before calculating
mean day, night, and 24-hour ambulatory blood pressure
values.
GFR was measured after a single intravenous injection
of 3.7 MBq chromium 51 ethylenediaminetetraacetic acid
(51Cr-EDTA) at 8:30 a.m. by determining the radioactiv-
ity in venous blood samples taken 180, 200, 220, and 240
minutes after injection [16]. The results were standard-
ized for 1.73 m2 body surface area, using the patient’s
surface area at the start of the study. The mean day-to-
day coefficient of variation is 4% in our laboratory.
From venous samples, hemoglobin concentration (Sys-
mex SF3000) (Sysmex Corporation, Kobe, Japan), and
plasma potassium, sodium, creatinine, and cholesterol
concentrations were determined (Hitachi 912 system),
and hemoglobin A1c (HbA1c) was measured by high-
performance liquid chromatography (HPLC) (normal
range 4.1% to 6.4%) (Tosoh Automated Glycohe-
moglobin Analyser) (Tosoh Bioscience, Minato, Japan).
Blood samples for plasma renin activity and aldosterone
concentrations were taken after 30 minutes of supine
rest. Plasma renin activity was measured by a method,
based on determining by radioimmunoassay, the amount
of angiotensin I generated, as previously described [17].
Plasma aldosterone was measured using a commercially
available radioimmunoassay (Coat-a-Count) (Diagnos-
tic Products Corporation, Los Angeles, CA, USA).
Statistical analysis
Before the present study, we calculated the SD (log
scale 0.1771) of the mean difference in UAE rate in three
consecutive 24-hour urine samples collected twice within
3 months in 36 diabetic patients with diabetic nephropa-
thy. On the basis of these data, a sample-size calcula-
tion revealed a necessary minimum of 50 patients to
detect a 15% difference in change in UAE rate between
any two dose levels (alpha = 0.05 and beta = 0.8). Re-
sults are expressed as mean (SE) unless otherwise stated.
UAE, fractional clearance of albumin, renin, and aldos-
terone were logarithmically transformed before analysis
due to its skewed distribution and are given as geomet-
ric mean with 95% confidence intervals. Comparisons
of clinical end points, including UAE, ambulatory blood
pressure, and GFR between each treatment period, were
performed using linear mixed models [18]. The adapted
model was one with fixed effects of treatment level, visit
and carryover (i.e., treatment level in the previous period)
and a random effect of person included to account for the
person dependencies in data. For the simplest models the
P value and effects correspond to results obtained from
paired t test and two-way analysis of variance (ANOVA),
but these models allow for more elaborate exploration of
the material. Tests for presence of effects were performed
as likelihood-ratio tests, and final estimates were reported
as Restricted Maximum Likelihood (REML) estimates.
Linear regression analysis was performed by the least
square method. The software used was R version 2.0.1
(http://www.r-project.org) and SPSS 13.0 (SPSS, Chicago,
IL, USA).
RESULTS
A total of 58 patients were included in the study.
Two patients were excluded during the initial 2-month
washout period due to increase in systolic blood
pressure above 180 mm Hg. Among the remaining
56 patients who were randomized to treatment with irbe-
sartan, four patients were excluded due to adverse clini-
cal events, which were not considered related to the study
medication as described in the safety section below. A to-
tal of 52 patients completed the trial and were included
in the present analysis. Baseline characteristics of these
patients are shown in Table 1.
Efficacy
UAE, fractional clearance of albumin, 24-hour blood
pressure, and GFR were all significantly reduced from
baseline by all three doses of irbesartan as shown in
Table 2. No significant carryover or treatment sequence
effects were found for any of these end points.
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Table 1. Baseline characteristics of 52 type 2 diabetic patients with
microalbuminuria randomized to treatment with irbesartan 300, 600
and 900 mg once daily
N = 52
Age yearsa 58 (10)
Known diabetes duration yearsa 13 (8)
Males/females 41/11
Body mass index kg/m2a 33 (5)
Diabetic retinopathy %
Nil 36
Simplex 58
Proliferative 6
Insulin treatment% 74
Low-dose aspirin% 94
Lipid-lowering treatment%b 87
aValues are mean (SD): bPredominantly statins.
UAE
The geometric mean (95% CI) of 24-hour UAE was
134 mg/24 hours (103 to 170) corresponding to 93 lg/min
(72 to 118). Reductions of 24-hour UAE from baseline
were 52% (46% to 57%), 49% (43% to 54%), and 59%
(54% to 63%) for irbesartan 300, 600, and 900 mg daily,
respectively (P < 0.01). Four-hour UAE and fractional
clearance of albumin were reduced to a similar extent by
the three doses (Table 2). The reductions from baseline in
UAE and fractional clearance of albumin were similar for
irbesartan 300 and 600 mg, whereas significantly greater
reductions were obtained by irbesartan 900 mg (Table 2).
The effect of increasing the dose of irbesartan from 300
to 900 mg was an additional reduction in 24-hour UAE
of 15% (95% CI 2% to 26%) from 64 mg/24 hours (49 to
84) to 54 mg/24 hours (43 to 68), in 4-hour UAE of 20%
(8% to 31%) from 42 lg/min (31 to 57) to 34 lg/min (26
to 44) and in fractional clearance of albumin of 15% (2%
to 26%) (P < 0.05 for all). Compared to 600 mg, the effect
of 900 mg was an additional reduction in 24-hour UAE of
20% (7% to 31%) from 68 mg/24 hours (53 to 86) to 54
mg/24 hours (43 to 68), 4-hour UAE of 24% (6% to 38%)
from 45 lg/min (35 to 60) to 34 lg/min (26 to 44), and
in fractional clearance of albumin of 22% (4% to 37%)
(P < 0.05 for all).
Patients with the greatest additional antiproteinuric ef-
fects of the highest dose (reductions in 24-hour UAE
above the median of 15% when irbesartan was increased
from 300 to 900 mg) were characterized by higher levels
of UAE both at baseline and during treatment with irbe-
sartan 300 mg as compared with patients having reduc-
tions in 24-hour UAE below the median. No other signif-
icant differences were found between these two groups,
including gender distribution, known diabetes duration,
and body mass index (BMI). In addition, the two groups
had similar levels of systemic blood pressure, GFR and al-
dosterone at baseline and during treatment with irbesar-
tan 300 mg and comparable reductions in blood pressure T
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Fig. 2. Linear regression analysis between
urinary albumin excretion rate (UAE) during
conventional treatment with irbesartan 300
mg once daily, and the relative change in UAE
(log10) when irbesartan was increased from
300 to 900 mg once daily (r=0.66,P<0.001).
The figure illustrates that the beneficial im-
pact on UAE of 900 mg irbesartan increases
with higher levels of UAE during treatment
with irbesartan 300 mg.
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Fig. 3. Reduction in urinary albumin excre-
tion (UAE) rate and fractional clearance of
albumin by increasing the dose of irbesar-
tan from the currently recommended dose of
300 mg daily to 900 mg daily in 52 type 2
diabetic patients with microalbuminuria. Pa-
tients have been stratified according to the
median level of 24-hour urinary albumin ex-
cretion (71 mg/24 hours) during treatment
with irbesartan 300 mg daily. Results for pa-
tients with 24-hour UAE above the median
during treatment with irbesartan 300 mg once
daily are shown by the black bars, whereas
the results for patients below the median are
shown by the gray bars. ∗P < 0.05. Bars indi-
cate 95% CIs of the mean difference.
GFR, and aldosterone when irbesartan was increased
from 300 to 900 mg.
As illustrated in Figure 2, there was a significant cor-
relation between the level of 24-hrs UAE during treat-
ment with irbesartan 300 mg and the relative reduction
of UAE when irbesartan was increased from 300 to 900
mg (r = 0.66, P < 0.001) suggesting that the higher the
level of UAE during conventional treatment with irbe-
sartan 300 mg the greater the antiproteinuric response
by increasing the dose of irbesartan to 900 mg. As also
depicted on Figure 2, the majority of the patients who did
not have an additional reduction in UAE when irbesartan
was increased from 300 to 900 mg, had UAE levels in the
normoalbuminuric range already on 300 mg irbesartan.
When stratifying patients above and below the median
value of 24-hour UAE of 71 mg/24 hours during treat-
ment with irbesartan 300 mg, patients above the median
had an additional reduction in 24-hour and 4-hour UAE
and fractional clearance of approximately 30% as com-
pared to the lack of effects in patients below the median
(Fig. 3).
There was also a significant correlation between base-
line level of 24-hour UAE and the additional reduction
in 24-hour UAE by increasing the dose from 300 to 900
mg (r = 0.63, P < 0.03). When stratifying patients above
and below the median baseline level of 24-hour UAE of
93 mg/24 hours, the mean reduction (95% CI) in 24-hour
UAE upon increasing the dose from 300 to 900 mg were
23% (5% to 38%) vs. 1 (−15% to 14%) (P < 0.05) for
patients above vs. below the median, respectively. Similar
results were obtained for fractional clearance of albumin.
The intraindividual variation of 24-hour UAE did not
correlate to the level of UAE, at any of the dose levels of
irbesartan (data not shown).
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Table 3. Effects on laboratory data of ultrahigh doses of irbesartan in 52 patients with type 2 diabetes and microalbuminuria
Irbesartan
Baseline 300 mg once daily 600 mg once daily 900 mg once daily
Renin activity ng/mL/hour 5 (4 to 6) 17 (13 to 23)a 22 (16 to 30)a,b 26 (19 to 35)a,b
Aldosterone pg/mL 72 (60 to 86) 67 (55 to 81) 51 (40 to 67)a 48 (36 to 63)a
Hemglobin A1c% 8.4 (0.2) 8.2 (0.2) 8.3 (0.2) 8.2 (0.2)
Plasma potassium mmol/L 3.6 (0.04) 3.9 (0.04)a 3.9 (0.05)a 4.0 (0.05)a,b,c
Plasma sodium mmol/L 138.5 (0.3) 137.5 (0.4)a 137.7 (0.4)a 137.5 (0.4)a
24-hour urinary sodium excretion mmol/L 203 (10) 213 (12) 215 (11) 216 (10)
Hemoglobin mmol/L 8.7 (0.1) 8.2 (0.1)a 8.2 (0.1)a 8.1 (0.1)a,b,c
Plasma total cholesterol mmol/L 4.32 (0.14) 4.04 (0.14)a 4.18 (0.10)a 4.00 (0.09)a
Plasma low-density lipoprotein cholesterol 2.61 (0.11) 1.88 (0.09)a 2.03 (0.09)a 1.94 (0.09)a
Plasma high-density lipoprotein cholesterol 1.21 (0.05) 1.25 (0.05)a 1.25 (0.05)a 1.24 (0.05)a
Plasma very low-density lipoprotein cholesterol 0.84 (0.06) 0.77 (0.06) 0.82 (0.06) 0.75 (0.06)a
Plasma triglycerides 2.05 (0.20) 1.87 (0.18) 1.94 (0.17) 1.81 (0.17)
Values are mean (SE).
aP < 0.05 vs. baseline; bP < 0.05 vs. irbesartan 300 mg; cP < 0.05 vs. irbesartan 600 mg.
Arterial blood pressure
The mean 24-hour blood pressure was reduced from
baseline by 8 (4 to 12) systolic and 6 (4 to 7) mm Hg di-
astolic during treatment with irbesartan 300 mg with no
significant additive effect of increasing the dose further
(Table 2). Besides a slightly lower diastolic blood pres-
sure of 2 mm Hg during the night by irbesartan 900 mg
as compared with 300 mg, no other significant differences
between the three doses were seen in arterial blood pres-
sure during the day or night (Table 2).
GFR
GFR was reduced from baseline by 4 mL/min/1.73 m2
(95% CI 1 to 7), 7 mL/min/1.73 m2 (4 to 11), and
8 mL/min/1.73 m2 (5 to 11) by increasing doses of irbesar-
tan (P < 0.05). There was a significantly greater decrease
in GFR of 3 to 4 mL/min/1.73 m2 by the two highest doses
as compared with the lowest dose (P < 0.05), with no sig-
nificant difference between the higher doses (Table 2).
Renin and aldosterone
There was a clear significant dose-dependent increase
in plasma renin activity from 5 ng/mL/hour (95%CI 4 to
6) at baseline to 17 ng/mL/hour (13 to 23), 22 ng/mL/hour
(16 to 30), and 26 ng/mL/hour (19 to 35) at 300, 600,
and 900 mg, respectively (P < 0.05). There was a similar
graded decrease in plasma aldosterone from 72 pg/mL
(60 to 86) at baseline to 67 pg/mL (55 to 81), 51 pg/mL
(40 to 67), and 48 pg/mL (36 to 63) with increasing doses
of irbesartan (NS for irbesartan 300 mg vs. baseline, and
P < 0.05 for irbesartan 600 and 900 mg vs. baseline)
(Table 3). In linear regression analysis changes in plasma
renin activity from baseline to each dose level of irbe-
sartan correlated significantly to changes in UAE (P val-
ues <0.05) but changes in plasma renin activity explained
only a small proportion of the variation in UAE (r values
between 0.10 and 0.15). There were no significant corre-
lations between changes in circulatory aldosterone levels
from baseline to each dose level of irbesartan and changes
in UAE.
HbA1c, sodium, and lipids
HbA1c was 8.4% (SE 0.2) at baseline and did not
change during treatment (Table 3). Plasma sodium de-
creased slightly from approximately 139 mmol/L at base-
line to 138 mmol/L during irbesartan treatment with
no significant differences between doses (Table 3). The
increase in urinary sodium excretion during irbesartan
treatment was not statistically significant from baseline
(Table 3). A dose-independent improved lipid profile
was obtained during irbesartan treatment with decreased
total- and low-density lipoprotein (LDL) cholesterol,
and increased high-density lipoprotein (HDL) choles-
terol levels (Table 3).
Safety
A total of four patients were excluded due to clini-
cal adverse events during treatment with irbesartan. One
63-year-old woman was excluded due to acute myocar-
dial infarction while receiving irbesartan 300 mg, respec-
tively, and two male patients (70 and 72 years of age,
respectively) were excluded due to ischemic stroke while
receiving irbesartan 300 and 900 mg, respectively. None
of these cardiovascular events were considered due to
changes in systemic arterial blood pressure upon treat-
ment with irbesartan since all patients had stable arterial
blood pressure between 110 to 170 mm Hg systolic and
60 to 90 mm Hg diastolic before and during the study.
One patient discontinued the study medication after
2 weeks on irbesartan 900 mg before any clinical exami-
nation was performed due to complaints of dizziness and
general discomfort. Among the 52 patients completing
the study, seven patients complained of mild and transient
dizziness upon irbesartan treatment: one patient during
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300 mg, three patients during 600 mg, and three during
900 mg.
There was a significant increase in baseline plasma
potassium of 0.3 mmol/L during treatment with irbesar-
tan 300 and 600 mg and by 0.4 mmol/L during treatment
with 900 mg (Table 3). However, none of the patients
included in the study developed hyperkalemia (plasma
potassium >5.5 mmol/L). Plasma hemoglobin decreased
significantly from 8.7 mmol/L at baseline to 8.2 mmol/L
during treatment with 300 and 600 mg and to 8.1 mmol/L
during irbesartan 900 mg (Table 3).
DISCUSSION
Our randomized double-blind crossover trial of 52 type
2 diabetic patients with microalbuminuria, demonstrates
that the full antiproteinuric potential of the ARB irbe-
sartan is not reached at the currently recommended dose
of 300 mg once daily. Further increase of the dose up to
900 mg once daily resulted in a more complete RAAS
blockade and additional reduction of UAE. The greater
reduction of UAE by higher doses of irbesartan was inde-
pendent of reductions in systemic blood pressure, which
was largely unaffected by doses exceeding 300 mg once
daily of irbesartan. Our study also suggests that patients
with the highest level of UAE during treatment with irbe-
sartan 300 mg are more likely to have additional benefit
from increased dosing. We also demonstrated a dose-
independent improvement in lipid profiles upon irbe-
sartan treatment with decreased total cholesterol and
LDL cholesterol. Since arterial blood pressure, albumin-
uria, and hyperlipidimia are established surrogate end
points for long-term cardiovascular outcome in diabetic
patients, our data suggest that blockade of the RAAS
may offer cardiovascular protection in these patients.
In our study the effects of each dose level were eval-
uated after 2 weeks up-titration with irbesartan 300 mg
followed by 8 weeks treatment at the full dose. Therefore,
if the maximal reduction in UAE and blood pressure is
not reached within 8 weeks, our results would underesti-
mate the true treatment effect. However, previous studies
of patients with both diabetic and nondiabetic nephropa-
thy have demonstrated that the maximal antiproteinuric
and antihypertensive effect by inhibition of the RAAS is
reached 3 to 4 weeks after initiation of therapy [19, 20].
Furthermore, the reduction in UAE after 10 weeks of
treatment with irbesartan 300 mg in our study was even
greater than the 38% reduction obtained after 2 years
of treatment with irbesartan 300 mg in the IRMA2 trial
[11]. Another potential bias in crossover studies relates
to the possible carryover effect, which would occur in the
present study, if the effect on the end points evaluated of
a given dose persists for more than 10 weeks after discon-
tinuation of the treatment. Such a carryover effect would
lead to an underestimation of the treatment effects pref-
erentially of higher doses. However, we could not detect
any significant carryover or time-sequence effect in the
statistical analysis of the present study or in our previous
studies of RAAS inhibition also applying similar treat-
ment intervals [21–23].
Several studies have demonstrated that the baseline
level of UAE as well as the initial reduction in albu-
minuria upon initiation of antihypertensive treatment are
strong predictors of the long-term cardiovascular and re-
nal outcome independent of changes in arterial blood
pressure (i.e., the greater the short-term reduction in
UAE the lower the long-term cardiovascular risk and
the slower the progression of renal disease [4–10]). In
this regard our data suggest that the full reno- and car-
diovascular protective potential of agents blocking the
RAAS may not be reached in patients with diabetic re-
nal disease when recommended doses of these agents are
extrapolated from their blood pressure–lowering prop-
erties, which is currently the case for all angiotensin-
converting enzyme (ACE) inhibitors and ARBs used for
renoprotection. By exceeding currently recommended
maximum dose, our results extend findings in previ-
ous dose-response studies of ACE inhibitors and ARBs
which has demonstrated that within the currently rec-
ommended dose interval higher doses provide greater
antiproteinuric effects than lower doses [11, 21, 24, 25].
The only other study of antiproteinuric effects of supra-
maximal doses of ARBS is a nonrandomized open-
labeled study of ten older patients with heavy proteinuria
(>1.5 g/day) of different etiology which in line with our
findings demonstrated an additional reduction in protein-
uria by exceeding the currently recommended maximum
dose of the ARB candesartan [26].
Several underlying mechanisms may explain the blood
pressure–independent antiproteinuric effects of agents
blocking the RAAS seen in our and several previous
studies [11–13, 27]. These include reduced intraglomeru-
lar hydraulic pressure independent of reduction of sys-
temic blood pressure by vasodilatation preferentially of
the postglomerular arterioles [28], and improved perms-
elective properties of the glomerular membrane [29]. In
addition, ARBs may prevent the occurrence of protein-
uria by reducing the loss of glomerular nephrin [30], and
by reducing renal levels of prosclerotic cytokines such as
transforming growth factor-b (TGF-b) and connective
tissue growth factor (CTGF) [31]. Increased RAAS ac-
tivity and augmented angiotensin II receptor density in
the diseased renal tissue together with reduced penetra-
tion of the drug may explain that higher doses are needed
for complete RAAS blockade in the tissue responsible for
antiproteinuric effects as compared to circulatory levels
regulating systemic blood pressure.
The additional reduction in plasma aldosterone found
in our study by increasing the dose of irbesartan above
300 mg once daily may provide further benefits in
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retarding progression of renal disease and reducing car-
diovascular risk. There is an accumulating amount of data
suggesting that not only angiotensin II but also aldos-
terone plays an important role for progression of renal
and cardiovascular disease [32–35].
The decrease in levels of cholesterol in our study
was obtained despite treatment with lipid-lowering drugs
which included mainly statins in the majority of the pa-
tients. Changes in cholesterol levels were in the same or-
der of magnitude as reported in a recent open-labeled
study of 16,600 type 2 diabetic patients treated with irbe-
sartan 300 mg daily [36].
High-dose irbesartan treatment was generally well tol-
erated in our study. Three serious cardiovascular events
occurred among 56 patients randomized to 30 weeks of
irbesartan treatment which corresponds to an annual car-
diovascular event rate of approximately 9%. This is in the
same order of magnitude as reported previously in type
2 diabetic patients with microalbuminuria [37], and re-
flects the high cardiovascular risk among these patients
rather than adverse events caused by the study medica-
tion. The safety of the currently recommended doses of
irbesartan up to 300 mg once daily is well documented in
diabetic patients [11, 13, 36]. Higher doses have not been
evaluated previously in diabetic renal disease but short-
term studies of patients with essential hypertension have
demonstrated good tolerability and a placebo-like safety
of irbesartan in doses up to 900 mg. In these studies side
effects were dose-independent [38]. A recent short-term
safety study of 12 patients with various forms of chronic
renal diseases with severe proteinuria also demonstrated
good tolerability of the ARB candesartan in doses five
times higher than the currently approved maximum dose
[39]. However, before extending the currently recom-
mended dose range of ARBs, the long-term safety still
remains to be carefully established.
In our study treatment with irbesartan induced a
significant increase in plasma potassium and a reduc-
tion in hemoglobin. However, these changes were only
marginally greater when exceeding the currently recom-
mended dose of irbesartan. Of note, none of the patients
developed hyperkalemia, which may in part be due to the
normal levels of GFR among the patients included in the
study and due to the concomitant use of diuretics in all
patients. Diuretics was also given to control blood pres-
sure and to reduce the risk of cardiovascular events [40]
and edema formation during the trial and diminishing
the influence of varying dietary salt intake on the effects
of irbesartan [41, 42]. The reduction in hemoglobin is in
agreement with previous findings [21] and is likely a di-
rect consequence of blocking the actions of angiotensin
II, which is known to stimulate erythropoietin synthe-
sis [43]. The decreased GFR during irbesartan treatment
represents a beneficial functional hemodynamic conse-
quence of the reduced systemic and glomerular blood
pressure. It does not indicate permanent renal function
loss as it is fully reversible upon withdrawal of treatment
as demonstrated previously [44] and as indicated in our
study by the lack of carryover effects on GFR.
CONCLUSION
Our study has demonstrated that the full antiprotein-
uric dose or irbesartan is not reached at the recommended
dose of 300 mg once daily in type 2 diabetic patients with
microalbuminuria. Increasing the dose up to 900 mg once
daily leads to a more complete RAAS blockade with ad-
ditional reduction of albuminuria independent of changes
in systemic blood pressure and GFR. Patients with the
highest levels of UAE during treatment with irbesartan
300 mg having the poorest renal and cardiovascular prog-
nosis are more likely to have additional benefit from in-
creased dosing. Future studies are needed to evaluate if
this finding can be extended to an equal or perhaps even
greater additional effect in patients with overt diabetic
nephropathy. Additional studies would also be needed
to establish if further antiproteinuric effects can be ob-
tained by even higher doses since a plateau of the dose-
response curve was not reached in our study even though
irbesartan was given in doses well beyond the currently
recommended dose.
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